Videos
Discussing Novel Imaging Outcomes in Multiple Sclerosis: Eric Klawiter, MD, MSc
February 17th 2022The director of the Multiple Sclerosis and Neuromyelitis Optica Unit at Massachusetts General Hospital outlined a presentation he gave at a recent Institutional Perspectives in Neurology: MS event. [WATCH TIME: 3 minutes]
Next Steps for ATA188, Research Related to EBV and Multiple Sclerosis: AJ Joshi, MD
February 17th 2022The chief medical officer at Atara Biotherapeutics provided insight on the future direction of its investigational agent ATA188 following new data that suggested a link between Epstein-Barr virus and multiple sclerosis. [WATCH TIME: 4 minutes]
Capabilities of Allegheny Health Network’s Expansive Headache Registry: Andrea Synowiec, DO
February 16th 2022The assistant director of the Allegheny Headache Center explained the origins of the recently launched headache registry, which keeps data about patients’ responses to medications. [WATCH TIME: 6 minutes]
Understanding Differences in B-Cell Depleting Medications for MS: Kristin Galetta, MD, MSEd
February 15th 2022The professor of neurology at Brigham and Women’s Hospital discussed her presentation on B-cell depleting therapies such as ocrelizumab and ofatumumab for the treatment of multiple sclerosis. [WATCH TIME: 2 minutes]
Using Telemedicine to Manage Psychosis in Neurodegenerative Diseases: George Grossberg, MD
February 15th 2022The Samuel W. Fordyce professor and director of Geriatric Psychiatry at the St. Louis University School of Medicine discussed the motivation behind recently published recommendations for clinicians who treat psychosis in neurodegenerative diseases in a telemedicine setting. [WATCH TIME: 4 minutes]
Managing Insomnia: Practical Advice for Community Physicians
Closing their discussion on insomnia, panelists share final thoughts and advice for community physicians.
Improving Insomnia Management: Novel Agents in the Pipeline
Expert panelists share their excitement for novel agents that may impact the insomnia treatment landscape.
Major Themes, Focuses at ACTRIMS 2022
February 11th 2022Jeffrey Cohen, MD, director, Mellen Center for MS Treatment and Research, Cleveland Clinic; and president, ACTRIMS, discussed what he is looking forward to at the 2022 ACTRIMS Forum, as well as the overarching themes of the meeting. [WATCH TIME: 2 minutes]
ATA188, Targeting EBV Antigens to Treat Progressive MS: AJ Joshi, MD
February 11th 2022The chief medical officer at Atara Biotherapeutics discussed the investigational agent ATA188, its mechanism to treat multiple sclerosis, and what to look for in its upcoming EMBOLD trial data readout. [WATCH TIME: 4 minutes]
Outline of New Cleveland Clinic Brain Study: Imad Najm, MD
February 10th 2022The director of Cleveland Clinic’s Epilepsy Center provided insight on a new 20-year initiative to uncover more about the origins of neurological diseases and how they occur prior to symptom onset. [WATCH TIME: 3 minutes]
Prime PD: A New Virtual Fitness Program for Parkinson Disease: Konstantin Karmazin, MD
February 10th 2022The chief medical officer of Prime PD spoke on motivations behind the development of the program and the unique benefits it offers amidst the ongoing COVID-19 pandemic. [WATCH TIME: 3 minutes]
Understanding the Epidemiological Connection Between MS and Epstein-Barr Virus: AJ Joshi, MD
February 9th 2022The chief medical officer at Atara Biotherapeutics detailed the clinical significance of a recently published paper in Nature that adds to the evidence that Epstein-Barr virus is the leading cause of multiple sclerosis. [WATCH TIME: 3 minutes]
Future Research on the Pathogenesis of COVID-19, Cognitive Changes: Joanna Hellmuth, MD, MS
February 8th 2022The cognitive neurologist at the University of California San Francisco discussed the need to continue research on why patients develop cognitive changes following COVID-19 infection and how clinicians can care for them. [WATCH TIME: 4 minutes]
Unmet Needs in the Management of Insomnia
A brief review of the unmet needs in insomnia management, particularly access to treatment and daytime functioning.
Factors in Selecting Pharmacologic Therapy for Insomnia
Practical considerations for selecting a particular agent or class when treating a patient with insomnia.
Optimizing Integrative Wellness Strategies for MS Through Research: Kathy Zackowski, PhD, OTR
February 6th 2022The senior director of patient management, care, and rehabilitation at the National Multiple Sclerosis Society discussed the steps needed to take to improve relatively new wellness strategies. [WATCH TIME: 3 minutes]
